Skip to main content
. 2016 Jun 15;6(9):1425–1439. doi: 10.7150/thno.15359

Figure 7.

Figure 7

3rd-Gen NanoVelcro CTC Chips for non-small cell lung cancer (NSCLC) CTC purification, followed by mutational analysis. (a) The workflow demonstrating 83 the use of 3rd-gen NanoVelcro Chip for non-small cell lung cancer CTC purification followed by detection of EGFR mutations. (b-d) Longitudinal data showed the mutational analysis of CTCs from a NSCLC patient. (c) L858R mutation was detected in CTCs and tumor tissues before gefitinib (1st-Gen EGFR inhibitor) treatment. Tumor regression was observed soon after initiation of gefitinib, as shown in (b). (d) The secondary T790M mutation was detected later in CTCs when the patient's disease progressed.